Measurement of detector-corrected observables sensitive to the anomalous production of events with jets and large missing transverse momentum in collisions at TeV using the ATLAS detector.

Observables sensitive to the anomalous production of events containing hadronic jets and missing momentum in the plane transverse to the proton beams at the Large Hadron Collider are presented. The observables are defined as a ratio of cross sections, for events containing jets and large missing transverse momentum to events containing jets and a pair of charged leptons from the decay of a boson. This definition minimises experimental and theoretical systematic uncertainties in the measurements.

Determination of the strong coupling constant from transverse energy-energy correlations in multijet events at using the ATLAS detector.

Measurements of transverse energy-energy correlations and their associated asymmetries in multi-jet events using the ATLAS detector at the LHC are presented. The data used correspond to proton-proton collisions with an integrated luminosity of 20.2 .

Search for direct top squark pair production in final states with two leptons in TeV collisions with the ATLAS detector.

The results of a search for direct pair production of top squarks in events with two opposite-charge leptons (electrons or muons) are reported, using of integrated luminosity from proton-proton collisions at TeV collected by the ATLAS detector at the Large Hadron Collider. To cover a range of mass differences between the top squark and lighter supersymmetric particles, four possible decay modes of the top squark are targeted with dedicated selections: the decay into a -quark and the lightest chargino with , the decay into an on-shell top quark and the lightest neutralino, the three-body decay and the four-body decay . No significant excess of events is observed above the Standard Model background for any selection, and limits on top squarks are set as a function of the and masses.

Precision measurement and interpretation of inclusive , and production cross sections with the ATLAS detector.

High-precision measurements by the ATLAS Collaboration are presented of inclusive , and ( ) Drell-Yan production cross sections at the LHC. The data were collected in proton-proton collisions at with an integrated luminosity of . Differential and cross sections are measured in a lepton pseudorapidity range .

Measurement of jet fragmentation in Pb+Pb and collisions at TeV with the ATLAS detector at the LHC.

The distributions of transverse momentum and longitudinal momentum fraction of charged particles in jets are measured in Pb+Pb and collisions with the ATLAS detector at the LHC. The distributions are measured as a function of jet transverse momentum and rapidity. The analysis utilises an integrated luminosity of 0.

Next generation metronomic chemotherapy-report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6-8 May 2016, Mumbai.

The 5 Biennial Metronomic and Anti-angiogenic Therapy Meeting was held on 6 - 8 May in the Indian city of Mumbai. The meeting brought together a wide range of clinicians and researchers interested in metronomic chemotherapy, anti-angiogenics, drug repurposing and combinations thereof. Clinical experiences, including many from India, were reported and discussed in three symposia covering breast cancer, head and neck cancers and paediatrics.

Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma.

Targeting tumor angiogenesis is a potential therapeutic strategy for glioblastoma because of its high vascularization. Tivozanib is an oral pan-VEGF receptor tyrosine kinase inhibitor that hits a central pathway in glioblastoma angiogenesis. We conducted a phase II study to test the effectiveness of tivozanib in patients with recurrent glioblastoma.

Measurement of the Inelastic Proton-Proton Cross Section at sqrt[s]=13 TeV with the ATLAS Detector at the LHC.

This Letter presents a measurement of the inelastic proton-proton cross section using 60  μb^{-1} of pp collisions at a center-of-mass energy sqrt[s] of 13 TeV with the ATLAS detector at the LHC. Inelastic interactions are selected using rings of plastic scintillators in the forward region (2.07<|η|<3.

Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients.

Unlabelled: Currently, no targeted therapies are available for metastatic triplenegative breast cancer (mTNBC). We evaluated the safety, efficacy, and biomarkers of response to cabozantinib, a multikinase inhibitor, in patients with mTNBC. We conducted a single arm phase II and biomarker study that enrolled patients with measurable mTNBC.

Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases.

The survival benefit of anti-vascular endothelial growth factor (VEGF) therapy in metastatic colorectal cancer (mCRC) patients is limited to a few months because of acquired resistance. We show that anti-VEGF therapy induced remodeling of the extracellular matrix with subsequent alteration of the physical properties of colorectal liver metastases. Preoperative treatment with bevacizumab in patients with colorectal liver metastases increased hyaluronic acid (HA) deposition within the tumors.

Reengineering the Tumor Microenvironment to Alleviate Hypoxia and Overcome Cancer Heterogeneity.

Solid tumors consist of cancer cells and stromal cells, including resident and transiting immune cells-all ensconced in an extracellular matrix (ECM)-nourished by blood vessels and drained by lymphatic vessels. The microenvironment constituents are abnormal and heterogeneous in morphology, phenotype, and physiology. Such irregularities include an inefficient tumor vascular network comprised of leaky and compressed vessels, which impair blood flow and oxygen delivery.

Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-β tyrosine kinase inhibitor, in patients with recurrent glioblastoma.

Background: Platelet-derived growth factor (PDGF) signaling is important in gliomagenesis and PDGF receptor-β is expressed on most endothelial cells in glioblastoma specimens.

Methods: We report the results of feasibility, phase I, and phase II studies of tandutinib (MLN518), an orally bioavailable inhibitor of type III receptor tyrosine kinases including PDGF receptor-β, Fms-like tyrosine kinase 3, and c-Kit in patients with recurrent glioblastoma.

Results: In an initial feasibility study, 6 patients underwent resection for recurrent glioblastoma after receiving tandutinib 500mg twice daily for 7 days.

Search for Higgs and Z Boson Decays to ϕγ with the ATLAS Detector.

A search for the decays of the Higgs and Z bosons to a ϕ meson and a photon is performed with a pp collision data sample corresponding to an integrated luminosity of 2.7  fb^{-1} collected at sqrt[s]=13  TeV with the ATLAS detector at the LHC. No significant excess of events is observed above the background, and 95% confidence level upper limits on the branching fractions of the Higgs and Z boson decays to ϕγ of 1.

Two Distinct Types of E3 Ligases Work in Unison to Regulate Substrate Ubiquitylation.

Hundreds of human cullin-RING E3 ligases (CRLs) modify thousands of proteins with ubiquitin (UB) to achieve vast regulation. Current dogma posits that CRLs first catalyze UB transfer from an E2 to their client substrates and subsequent polyubiquitylation from various linkage-specific E2s. We report an alternative E3-E3 tagging cascade: many cellular NEDD8-modified CRLs associate with a mechanistically distinct thioester-forming RBR-type E3, ARIH1, and rely on ARIH1 to directly add the first UB and, in some cases, multiple additional individual monoubiquitin modifications onto CRL client substrates.

Role of stromal cell-derived factor 1α pathway in bone metastatic prostate cancer.

Metastatic prostate cancer is one of the leading causes of cancer-related death in men. The primary site of metastasis from prostate cancers is the bone. During the last decade, multiple studies have pointed to the role of the stromal cell-derived factor 1 alpha (SDF1α)/CXCR4 axis in the metastatic spread of the disease, but the mechanisms that underlie this effect are still incompletely understood.

Immune modulation by hypofractionated stereotactic radiation therapy: Therapeutic implications.

Stereotactic body radiation therapy (SBRT) has become an attractive treatment modality and a safe, non-invasive alternative to surgery to control primary or secondary malignant tumors. While emphasis has been on the local tumor control as a treatment objective for SBRT, the rare but intriguing observations of abscopal (or out-of-field) effects have pointed to the exciting possibility of activating anti-tumor immunity by using high-dose radiation. This review summarizes the available evidence supporting immune modulation by SBRT alone, as well as its potential combination with immunotherapy.

Identification of boosted, hadronically decaying bosons and comparisons with ATLAS data taken at [Formula: see text] TeV.

This paper reports a detailed study of techniques for identifying boosted, hadronically decaying bosons using 20.3 fb[Formula: see text] of proton-proton collision data collected by the ATLAS detector at the LHC at a centre-of-mass energy [Formula: see text]. A range of techniques for optimising the signal jet mass resolution are combined with various jet substructure variables.

Tissue Microbiome Profiling Identifies an Enrichment of Specific Enteric Bacteria in Opisthorchis viverrini Associated Cholangiocarcinoma.

Cholangiocarcinoma (CCA) is the primary cancer of the bile duct system. The role of bile duct tissue microbiomes in CCA tumorigenesis is unestablished. To address this, sixty primary CCA tumors and matched normals, from both liver fluke (Opisthorchis viverrini) associated (OVa, n=28) and non-O.

Observation of Long-Range Elliptic Azimuthal Anisotropies in sqrt[s]=13 and 2.76 TeV pp Collisions with the ATLAS Detector.

ATLAS has measured two-particle correlations as a function of the relative azimuthal angle, Δϕ, and pseudorapidity, Δη, in sqrt[s]=13 and 2.76 TeV pp collisions at the LHC using charged particles measured in the pseudorapidity interval |η|<2.5.

Measurement of the charge asymmetry in top-quark pair production in the lepton-plus-jets final state in collision data at [Formula: see text] with the ATLAS detector.

This paper reports inclusive and differential measurements of the [Formula: see text] charge asymmetry [Formula: see text] in [Formula: see text] of [Formula: see text][Formula: see text] collisions recorded by the ATLAS experiment at the Large Hadron Collider at CERN. Three differential measurements are performed as a function of the invariant mass, transverse momentum and longitudinal boost of the [Formula: see text] system. The [Formula: see text] pairs are selected in the single-lepton channels ( or [Formula: see text]) with at least four jets, and a likelihood fit is used to reconstruct the [Formula: see text] event kinematics.

Search for direct top squark pair production in final states with two tau leptons in collisions at [Formula: see text] TeV with the ATLAS detector.

A search for direct pair production of the supersymmetric partner of the top quark, decaying via a scalar tau to a nearly massless gravitino, has been performed using 20 fb[Formula: see text] of proton-proton collision data at [Formula: see text]. The data were collected by the ATLAS experiment at the LHC in 2012. Top squark candidates are searched for in events with either two hadronically decaying tau leptons, one hadronically decaying tau and one light lepton, or two light leptons.

Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival.

Inhibition of the vascular endothelial growth factor (VEGF) pathway has failed to improve overall survival of patients with glioblastoma (GBM). We previously showed that angiopoietin-2 (Ang-2) overexpression compromised the benefit from anti-VEGF therapy in a preclinical GBM model. Here we investigated whether dual Ang-2/VEGF inhibition could overcome resistance to anti-VEGF treatment.

Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages.

Glioblastomas (GBMs) rapidly become refractory to anti-VEGF therapies. We previously demonstrated that ectopic overexpression of angiopoietin-2 (Ang-2) compromises the benefits of anti-VEGF receptor (VEGFR) treatment in murine GBM models and that circulating Ang-2 levels in GBM patients rebound after an initial decrease following cediranib (a pan-VEGFR tyrosine kinase inhibitor) administration. Here we tested whether dual inhibition of VEGFR/Ang-2 could improve survival in two orthotopic models of GBM, Gl261 and U87.

A protein and mRNA expression-based classification of gastric cancer.

The overall survival of gastric carcinoma patients remains poor despite improved control over known risk factors and surveillance. This highlights the need for new classifications, driven towards identification of potential therapeutic targets. Using sophisticated molecular technologies and analysis, three groups recently provided genetic and epigenetic molecular classifications of gastric cancer (The Cancer Genome Atlas, 'Singapore-Duke' study, and Asian Cancer Research Group).